1 February 2018 · Novo Nordisk A/S
Novo Nordisk Ozempic (monthly, list)
Approved for diabetes. The other use came later.
You bought the product
$850
Launch price, Feb 2018
You bought the shares instead
$1,599
Valued 6 Nov 2026
- Return on the launch price
- 1.88×
- Annualised
- 7.5%
- Years held
- 8.8
NYSE-listed ADR. Underlying listing is Copenhagen NOVO-B.